ArticleBMC anesthesiology2026
Cytomegalovirus DNAemia as a prognostic marker in critically ill hematopoietic stem cell transplant recipients with lower respiratory tract infection.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn Hematopoietic Stem Cell Transplantation (HSCT) recipients, Lower Respiratory Tract Infection (LRTI) is a leading cause of Intensive Care Units (ICU) admission and mortality. Although Cytomegalovirus (CMV) reactivation is a known risk factor for worse outcomes in HSCT recipients, the specific prognostic impact of CMV DNAemia on critically ill HSCT recipients with LRTI is not well-defined. This study aimed to determine the relationship between plasma CMV DNA levels at ICU admission and mortality in this high-risk population.
methodsThis retrospective study collected adult patients who have admitted to a single-center ICU received HSCT and were diagnosed with LRTI. Based on plasma CMV DNA levels tested within 48 h of admission, patients were grouped as CMV positive (> 103 copies/mL) or CMV negative (≤ 103 copies/mL). We performed a 1:1 propensity score matching to control for confounding factors. The primary outcome was ICU mortality. Secondary outcomes including 1-year mortality, ventilator-free days, and ICU length of stay. Survival of CMV positive or negative patients was examined with Cox regression.
resultsFrom 606 eligible patients, each of 155 patients were matched for the two groups by propensity score matching. The CMV positive group exhibited a significantly higher ICU mortality rate compared to the CMV negative group (32.35% vs. 25.80%, P = 0.011). A Cox regression analysis, adjusted for age, WBC count, SOFA score, PaO₂/FiO₂, and GvHD, confirmed that CMV positivity was independently associated with a higher risk of 1-year mortality (HR = 1.27, 95% CI [1.10–2.33], P = 0.002). The ventilator-free days and ICU length of stay did not significantly differ between the two groups.
conclusionIn HSCT recipients admitted to the ICU with LRTI, CMV DNAemia at admission is an independent predictor of both short-term and long-term mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.